EMEA-003160-PIP01-21 - paediatric investigation plan

Camidanlumab tesirine

Key facts

• Active Substance:
  Camidanlumab tesirine
• Therapeutic area:
  Oncology
• Decision number:
  P/0484/2022
• PIP number:
  EMEA-003160-PIP01-21
• Pharmaceutical form(s):
  Powder and solvent for concentrate for solution for infusion
• Condition(s) / indication(s):
  Treatment of Hodgkin lymphoma
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  ADC Therapeutics SA

  Email: [e-mail]; Tel. [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  02/12/2022

Decision

P/0484/2022: EMA decision of 2 December 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for camidanlumab tesirine (EMEA-003160-PIP01-21)

AdoptedReference Number: P/0484/2022